主要應用領域
Biotechnology
產品/服務
There are more than 7,000 orphan diseases in existence today, and yet only about 5% of them have treatment available. We recognize the tremendous unmet medical needs and a real opportunity to make a meaningful difference in the lives of these patients and families. As such, LifeMax dedicates itself to the development of first-in-class or best-in-class therapeutics for orphan diseases. Through licensing and collaboration, we have built a robust and science-driven portfolio that addresses critical unmet medical needs for the treatment of orphan diseases. We continue to expand the pipeline with a focus on modalities that target the underlying genetic cause. With its robust pipeline and seasoned management team, LifeMax is well positioned to grow into a leader in the development and commercialization of novel orphan drugs.
成立年份
2014
統一編號
24747226
公司狀態
營運中
負責人
許中強(HSU Chung-Chiang)
團隊人數
0
實收資本額
14,018,370 (元/新臺幣)
成立年份、公司狀態、負責人、實收資本額、註冊地址均來自「經濟部商業發展署 全國商工行政服務入口網」
註冊地址
臺北市大安區敦化南路2段97號2樓
網站連結
會員專屬內容
會員專屬內容，觀看前請先登入會員
公司簡介
LifeMax is a privately held, clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases that have few or no options. Our lead program, LM-030, is ready to enter into a pivotal trial for the treatment of Netherton syndrome.
LifeMax was established by four founders, led by Dr. Larry Hsu, a well-known entrepreneur and industry veteran, with a goal to build a company that would become a leader in the development and commercialization of much needed therapeutics to address critical unmet medical needs. LifeMax distinguishes itself from other biotech companies with an experienced management team that has a proven track record of having successfully built a fully integrated multi-billion dollar NASDAQ-listed US pharmaceutical company.
LifeMax was established by four founders, led by Dr. Larry Hsu, a well-known entrepreneur and industry veteran, with a goal to build a company that would become a leader in the development and commercialization of much needed therapeutics to address critical unmet medical needs. LifeMax distinguishes itself from other biotech companies with an experienced management team that has a proven track record of having successfully built a fully integrated multi-billion dollar NASDAQ-listed US pharmaceutical company.
